Media Mentions

Arizona Family recently featured the Ivy Brain Tumor Center and Dr. Nader Sanai, who highlighted the seriousness of glioblastoma (GBM). Lanette Veres, a brain tumor survivor diagnosed with a grade 3 glioma in 1998, shared her inspiring journey of resilience after losing her grandmother to GBM. Veres founded the Gray Matters Foundation in 2007 to support brain cancer patients and remains hopeful about new treatments, stating, “Hope never grows old.” Our Phase 3 Gliofocus Study testing the drug Niraparib, has shown promising results in early trials. Watch now!

FOX 10 Phoenix recently featured a segment on the Ivy Brain Tumor Center, highlighting the journey of patient Katie Reed and insights from Deputy Director, Shwetal Mehta, PhD. The discussion focused on the challenges of glioblastoma, an aggressive brain cancer, and the urgent need for new treatments and a cure. This segment underscores the critical work being done to advance research and provide hope to patients facing this daunting diagnosis. Watch now!

BrainWise recently featured the Ivy Brain Tumor Center in the article "Understanding Brain Tumors," where Dr. Yoshie Umemura, Chief of Neuro-Oncology at Barrow Neurological Institute and Chief Medical Officer at the Ivy Center, discusses the differences between primary and secondary brain tumors. Read more!

Clinical Trials Arena spotlighted the Ivy Brain Tumor Center at Barrow Neurological Institute, which has begun the Phase III Gliofocus trial of niraparib for recently diagnosed MGMT-unmethylated glioblastoma. Supported by GSK, the trial will involve 450 subjects across over 100 sites in 11 countries. Positive data from earlier trials led to this advancement. The study will compare niraparib’s efficacy to the standard chemotherapy, temozolomide. Dr. Nader Sanai, Director of the Ivy Center, highlighted the trial's potential to improve glioblastoma treatment outcomes.

Channel 12News recently featured Marie Donahue, a dedicated U.S. Navy member and patient at the Ivy Brain Tumor Center, in honor of Brain Tumor Awareness Month. Despite facing a daunting brain tumor diagnosis, Marie has tackled every day with an adventurous spirit and a renewed outlook on life. Watch her inspiring story now!

Endpoints News featured The Ivy Brain Tumor Center’s Phase 0/2 study of niraparib, GSK’s PARP inhibitor, in newly diagnosed glioblastoma patients. This study had promising results and has led the Ivy Brain Tumor Center and GSK to collaborate on a Phase 3 study of niraparib versus temozolomide in MGMT-unmethylated glioblastoma. Read more!

Good Morning Arizona spotlighted the Ivy Brain Tumor Center at Barrow Neurological Institute in recognition of Brain Tumor Awareness Month. As part of this initiative, Cold Beer and Cheeseburgers has teamed up with the Ivy Center for their annual Dine & Donate campaign. This partnership plays a crucial role in advancing vital research efforts aimed at combating brain tumors. Learn more about how you can support this important cause.

Phoenix Magazine has recognized Jacki Garcia, Nurse Educator at the Ivy Brain Tumor Center, as a 2024 Healthcare Hero. Jacki has played a crucial role in supporting our brain tumor patients through their brain cancer journeys with profound compassion and empathy.

Precision Medicine Online's article covered the Ivy Center's groundbreaking findings at the American Association for Cancer Research's annual meeting. Dr. Sanai's Phase 0/1 trial demonstrated the efficacy of AstraZeneca's AZD1390 in treating glioblastoma. These findings offer new hope for patients with limited treatment options. Learn more!

Endpoints News highlighted Dr. Nader Sanai’s groundbreaking research with AstraZeneca's AZD1390 in glioblastoma treatment at AACR 2024. The Phase 0 study, led by Dr. Sanai, Director of the Ivy Brain Tumor Center, demonstrates the drug's efficacy in penetrating brain tissue—a pivotal advancement in glioblastoma therapy. Learn more!